The Canadian government this week approved the prescription sale of a liquid marijuana extract to treat symptoms of multiple sclerosis, the Washington, D.C.-based Marijuana Policy Project reports. Sativex, produced by U.K. firm GW Pharmaceuticals, is a whole-plant extract that contains all of the naturally occurring compounds called cannabinoids that are found in marijuana plants.
(der volle Artikel bei advocate.com)